We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Biosensor Integrated in Active Microfluidic Cartridge Allows Superior Screening Possibilities

By LabMedica International staff writers
Posted on 06 Jan 2010
A polymer-based sensor integrated into an active microfluidic cartridge will allow simpler, faster, and systematic screening possibilities. More...
The new concept for diagnosis will permit, for example, doctors to diagnose a disease such as cancer, using only few microliters of blood taken from a patient.

The integration of sensing functionality as well as assay functionality into a compact fully-integrated cartridge-like device allowed transferring complexity from the macro to the micro system, leading to a Lab-on a-Chip. A polymer based technology platform was developed; it applies a label-free optical detection based on surface plasmon resonance (SPR).

Integrated into the cartridge the optical components (light source, waveguide, and detector) and fluidic elements for active liquid transport make it very suitable for diagnostics. The final product will be manufactured using large scale, mass production techniques resulting in a cartridge that will be inexpensive, disposable, and sensitive.

The polymer-based sensor the Plasmon enhanced SPR is being developed by the Surface Enhanced Micro Optical Fluidic Systems (SEMOFS) project (Chemnitz, Germany), supported by the European Commission with EUR 1.9 million in funding. The consortium of the project involves multidisciplinary expertise split among eight partners from five European countries, Switzerland, Belgium, Germany, France, and the UK.

SEMOFS was finished in February 2009, and tangible achievements have been reached. The hardware components of the integrated approach are technically operable. The cost estimations show that the cost target of less than EUR 50 is within reach. The concept is considered as being feasible for the new integrated biosensor approach. Some of the aspects targeted in the project need to be studied in more detail; these include the integration of all components into a single device to allow for example, clinical testing for cancer.

In order to begin utilizing project results it will be necessary to apply the components in several different applications, such as: excitation, microfluidic, polymer photodiode array for the low cost spectrometer, fast optimization in plasmonic devices design, and surface coating.

Related Links:
SEMOFS



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Real-Time PCR System
Gentier 96T
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.